National and Kapodistrian University of Athens
Ο ρόλος των αρχέγονων ενδοθηλιακών κυττάρων σε διαβητικούς ασθενείς με και χωρίς στεφανιαία νόσο
Abstract
dc:descriptionPurpose: Endothelial progenitor cells (EPCs) originating from the bone marrow playa significant role in neovascularization of ischemic tissues and in re-endotheliazationof injured blood vessels. The purpose of this study was to investigate if theadministration of pioglitazone or perindopril in diabetic patients can modify thenumber of EPCs in the peripheral blood and alter the endothelial function andinflammatory status of these patients.Methods: Fifty type 2 diabetic patients were recruited and were randomly assigned toreceive either pioglitazone (15mg/day) or perindopril (4mg/day) for a one-monthperiod. In both groups blood sample were drawn on admission (baseline) and afterone month of drug’s administration. Blood samples were taken in order to count EPCsand inflammation markers such as C-reactive protein (hsCRP), vascular endothelialgrowth factor (VEGF) and asymmetric dimethilarginine (ADMA). Circulating EPCswere defined by the surface markers CD34+/KDR/CD133 (CD34 and VEGFR2expressing cells) and analyzed by flow-cytometry. Moreover the endothelial functionof the patients was evaluated both on admission and after treatment with flowmediated dilation (FMD).Results: We have found that neither pioglitazone (p=0.09), nor perindopril (p=0.5)affected the number of EPCs. Importantly, we have shown that pioglitazone reducedCRP (p=0.04) and ADMA levels (p=0.002). In addition, pioglitazone improved FMD(p=0.04) and increased plasma concentrations of VEGF (p=0.01). On the contrary perindopril had no significant effect on CRP levels (p=0.07), FMD (p=0.23) as wellas on ADMA levels (p=0.09). However, perindopril administration increasedsignificantly plasma levels of VEGF (p=0.03). Moreover, in the present study weaimed to compare the effects of the different treatments on the aforementionedparameters (absolute changes, delta, Δ). Our results showed that although pioglitazonehad a significant beneficial effect on all the study markers, no significant differencewas observed in the absolute changes between the 2 agents. Moreover, both agentsdid not differ regarding to their effect on ΔEPCs (p=0.34), ΔFMD (p=0.70), ΔVEGF(p=0.27) and ΔCRP (p=0.85). Interestingly, we have found that perindopril had asuperior effect than that of pioglitazone considering ΔADMA levels (p=0.01), despitethe non significant (post administration) effect on ADMA levels resulting solely.Conclusions: Based on the existing data, it seems that both treatments did not affectsignificantly number of circulating endothelial cells. Importantly, pioglitazoneaffected beneficially all the study parameters. On the other hand, perindoprilincreased significantly only VEGF levels, while CRP, FMD and ADMA levels wereunaffected. Interestingly, we found that although perindopril had no significant effecton ADMA levels, this effect was greater when compared to that of pioglitazone.Considering our results, we provide also evidence for a possible addition ofperindopril to the conventional treatment with pioglitazone which could affect furtherthe neovascularization and reduce oxidative stress in these patients.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Kampoli, Anna-Maria
- Καμπόλη, Άννα-Μαρία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/29672